Watch AVTX. Know when insiders buy.
One email the day a filing lands. Free.
Work order
48
WATCH · insiders 49, shorts 47
Insiders, 90 days
−$14K
net selling · 0 buys, 1 sell
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $1BP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$100.3MNET CASH $70M52W 9.76 – 22.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$31.5M | −$36.4M | — | -0.83 | −$20M | — | — | Aug 6 |
| Q1 2026 · Mar 31 | — | — | — | −$20.9M | −$19.6M | — | -0.98 | −$17.7M | — | — | May 13 |
| Q4 2025 · Dec 31derived | $59K | −69.3% | — | −$19.7M | −$13.7M | — | -0.37 | −$14.2M | — | — | Mar 23 |
| Q3 2025 · Sep 30 | $0 | −100.0% | — | −$19.2M | −$30.6M | −232.9% | -2.19 | −$16.4M | — | — | Nov 6 |
| Q2 2025 · Jun 30 | — | — | — | −$19.3M | −$20.8M | −121.1% | -1.92 | −$11.4M | — | — | Aug 6 |
| Q1 2025 · Mar 31 | — | — | — | −$14.7M | −$13.1M | — | -1.25 | −$9.5M | — | — | May 13 |
| Q4 2024 · Dec 31derived | $192K | −66.4% | — | −$13.3M | −$35.3M | — | 1.72 | −$15M | $0 | −$15M | Mar 23 |
| Q3 2024 · Sep 30 | $249K | +5.5% | 386.7% | −$12.9M | $23M | — | -2.83 | −$11.5M | $0 | −$11.5M | Nov 6 |
| Q2 2024 · Jun 30 | $0 | — | — | −$9.6M | $98.5M | — | -14.07 | −$16.3M | $0 | −$16.3M | Aug 7 |
| Q1 2024 · Mar 31 | $0 | — | — | −$32.8M | −$121.3M | — | -141.14 | −$6.2M | $0 | −$6.2M | May 12 |
| Q4 2023 · Dec 31derived | $571K | — | 138.7% | −$7.7M | −$8.2M | — | 117.47 | −$2.8M | $0 | −$2.8M | Mar 20 |
| Q3 2023 · Sep 30 | $236K | — | -4.7% | −$3.8M | −$5.2M | — | -26.83 | −$6.8M | $0 | −$6.8M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $59K | — | −$72.9M | −$78.3M | -132642.4% | -5.84 | −$51.5M | — | — | — | — |
| FY2024 · to Dec 31 | $441K | — | −$68.5M | −$35.1M | -7965.8% | -20.91 | −$49.1M | $0 | −$49.1M | — | — |
| FY2023 · to Dec 31 | $1.9M | 33.3% | −$27.4M | −$31.5M | -1639.5% | -113.58 | −$30.7M | $158K | −$30.8M | — | — |
| FY2022 · to Dec 31 | $18.1M | 81.0% | −$37.4M | −$41.7M | -230.8% | -1063.00 | −$26.8M | $95K | −$26.8M | — | — |
| FY2021 · to Dec 31 | $5.4M | 72.4% | −$82.1M | −$84.4M | -1563.1% | — | −$70.9M | $113K | −$71M | — | — |
| FY2020 · to Dec 31 | $6.7M | 95.5% | −$72.8M | −$63.5M | -947.9% | — | −$40.5M | $63K | −$40.6M | — | — |
Every number comes from Avalo Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.